CVRx, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022 and Provides Revenue Guidance for the First Quarter and Full Year of 2023
January 09, 2023 at 07:15 pm IST
Share
CVRx, Inc. provided preliminary unaudited revenue guidance for the fourth quarter and full year of 2022 and provides revenue guidance for the first quarter and full year of 2023. For the fourth quarter of 2022, the company expects total revenue to be in the range of approximately $7.0 million to $7.1 million, representing an increase of approximately 91% to 94% over fourth quarter 2021 revenue of $3.66 million. Total revenue generated is expected to be made up of approximately $5.9 million in U.S. heart failure revenue, $1.2 million in European revenue and $26,000 in U.S. legacy revenue.
For the full year of 2022, the company expects total revenue to be in the range of approximately $22.3 million to $22.4 million, representing an increase of approximately 71% to 72% over full year 2021 revenue of $13.04 million. Total revenue generated is expected to be made up of approximately $17.5 million in U.S. heart failure revenue, $4.4 million in European revenue and $0.45 million in U.S. legacy revenue.
For the first quarter of 2023, the company expects total revenue to be between $7.1 million to $7.5 million.
For the full year of 2023, the company expects total revenue to be between $35.0 million to $38.0 million.
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
CVRx, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022 and Provides Revenue Guidance for the First Quarter and Full Year of 2023